Edible vaccines mark a groundbreaking approach to immunization by harnessing plant-based resources for vaccine development. Unlike conventional injections, these vaccines are ingested through genetically modified plants. This innovative strategy aims to improve accessibility, lower costs, and streamline vaccine distribution, particularly in regions with limited resources. The edible vaccine process involves introducing a specific gene into the plant's genetic code, enabling it to produce a vaccine protein. The potential of administering vaccines orally eliminates the necessity for injections, offering a more convenient and less invasive method of immunization. Edible vaccines present notable advantages, including heightened stability, simplified transportation, and reduced reliance on cold storage. Moreover, they hold the potential to overcome challenges associated with needle-based vaccination, fostering greater acceptance and participation in immunization initiatives. Ongoing research and development in this field may herald a transformative shift in global vaccination strategies, addressing health disparities and promoting extensive immunization coverage.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom